Gossamer Bio has sold rights to an experimental drug that could rival a new medicine from Merck & Co., in a deal at least one analyst believes “bodes well” for the company. On Monday, Gossamer and ...

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines given in the U.S. this ...

Many proposals to reform the PBM industry miss the forest for the trees, experts said this week. Instead, Congress should go ...